B-type Natriuretic Peptide Is Not a Marker of Ischemia During Dobutamine Stress Echocardiography

Journal of the American Society of Echocardiography

Volumn 20, Issue 1, 2007, Pages 23-26

  Salinas, Guillermo ^a   Daher, Iyad N ^a   Okorodudu, Anthony O ^a   Ahmad, Masood ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE;

ARTICLE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EXERCISE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; STRESS ECHOCARDIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY DISEASE; ECHOCARDIOGRAPHY, STRESS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 33845967500     PISSN: 08947317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.echo.2006.07.001     Document Type: Article

References (37)

1. Sudoh T., Kangawa K., Minamino N., and Matsuo H. A new natriuretic peptide in porcine brain. Nature 332 (1988) 78-81
2. Hosoda K., Nakao K., Mukoyama M., Saito Y., Jougasaki M., Shirakami G., et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension 17 (1991) 1152-1155
3. Yasue H., Yoshimura M., Sumida H., Kikuta K., Kugiyama K., Jougasaki M., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195-203
4. Stein B.C., and Levin R.I. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 135 (1998) 914-923
5. Azzazy H., and Christenson R. B-type natriuretic peptide: physiologic role and assay characteristics. Heart Fail Rev 8 (2003) 315-320
6. McCullough P.A., Omland T., and Maisel A.S. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 4 (2003) 72-80
7. Omland T., Persson A., Ng L., O'Brien R., Karlsson T., Hertlitz J., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
8. Edwards B.S., Zimmerman R.S., Schawb T.R., Heublein D.M., and Burnett Jr. J.C. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 62 (1988) 191-195
9. Brunea B.G., Piazza L.A., and de Bold A.J. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 273 (1997) H2678-H2686
10. Wiese S., Breyer T., Dragu A., Wakili R., Burkard T., Schmidt-Schweda S., et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 102 (2000) 3074-3079
11. Marumuto K., Hamada M., and Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Colch) 88 (1995) 551-556
12. Sabatine M.S., Morrow D.A., de Lemos J.A., Omland T., Desai M.Y., Tanasijevic M., et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44 (2004) 1988-1995
13. Toth M., Vuorinen K.H., Voulteenaho O., Hassinen I.E., Uussimaa P.A., Leppaluoto J., et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 266 (1994) H1572-H1580
14. Foote R.S., Pearlman J.D., Siegel A.H., and Yeo K.T. Detection of exercise induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 44 (2004) 1980-1987
15. Asada J., Tsuji H., Iwasaka T., Thomas J.D., and Laur M.S. Usefulness of plasma brain natriuretic peptide levels I predicting dobutamine-induced myocardial ischemia. Am J Cardiol 93 (2004) 702-704
16. Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G., Poole-Wilson P.A., et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350 (1997) 1349-1353
17. Cowie M.R., and Mendez G.F. BNP and congestive heart failure. Prog Cardiovasc Dis 44 (2002) 293-321
18. Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., and Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 47 (1997) 287-296
19. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin 19 (2001) 557-571
20. McDonagh T.A., Robb S.D., Murdoch D.R., Morton J.J., Ford I., Morrison C.E., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
21. Muders F., Kromer E.P., Griese D.P., Pfeifer M., Hense H.W., Riegger G.A., et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 134 (1997) 442-449
22. Wei T., Zeng C., Chen L., Chen Q., Zhao R., Lu G., et al. Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail 7 (2005) 75-79
23. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
24. Kikuta K., Yasue H., Yoshimura M., Morita E., Sumida H., Kato H., et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 132 (1996) 101-107
25. Morita E., Yasue H., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T., et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88 (1993) 82-91
26. Nagaya N., Nishikimi T., Goto Y., Miyao Y., Kobayashi Y., Morii I., et al. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 135 (1998) 21-28
27. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929
28. Sabatine M.S., Morrow D.A., de Lemos J.A., Gibson C.A., Murphy S.A., Rifai N., et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105 (2002) 1760-1763
29. Talwar S., Squire I.B., Downie P.F., Davies J.E., and Ng L.L. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 84 (2000) 421-424
30. Morrow D., de Lemos J.A., Sabatine M.S., Murphy S.A., Demopoulos L.A., DiBattiste P.M., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
31. Nakamura T., Sakamoto K., Yamano T., Kikkawa M., Zen K., Hikosaka T., et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 39 (2002) 1657-1663
32. Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., and Whooley M.A. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the heart and soul study. Circulation 108 (2003) 2987-2992
33. Cohen J.L., Ottenweller J.E., George A.K., and Duvuri S. Comparison of dobutamine and exercise echocardiography for detecting coronary artery disease. Am J Cardiol 72 (1993) 1226-1230
34. Mairesse G.H., Vanoverschelde J.L., Robert A., Climov D., Detry J.M.R., and Marwick T.H. Pahtophysiologic mechanism underlying dobutamine and exercise induced wall motion abnormalities. Am Heart J 136 (1998) 63-70
35. Navare M.N., and Thompson P.D. Acute cardiovascular response to exercise and its implication for exercise testing. J Nucl Cardiol 10 (2003) 521-528
36. Vanoverschelde J.L., Wijns W., Essamri B., et al. Hemodynamic and mechanical determinants of myocardial O2 consumption in normal human heart: effects of dobutamine. Am J Physiol 265 (1993) H1884-H1892
37. Barbato E., Bartunek J., Wyffels E., Wijns W., Heyndrickx G.R., and De Bruyne B. Effects of intravenous dobutamine on coronary vasomotion in humans. J Am Coll Cardiol 42 (2003) 1596-1601